Remy Burcelin
Metabolic and Cardiovascular Diseases
INSERM-French Institute of Health and Medical Research
France
Biography
He is a director of Institut des Maladies Métaboliques et Cardiovasculaires. Dr. Brucelin's team aims at identifying the intestinal risk factors which control glycemia, dyslipidemia and heart failure.
Research Interest
Biotechnology, Cell Biology, Endocrinology
Publications
-
Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J. E., Tercé, F., & Burcelin, R. (2017). A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metabolism, 25(5), 1075-1090.
-
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., ... & Xifra, G. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nature Medicine.
-
Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J. E., Tercé, F., & Burcelin, R. (2017). A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism. Cell Metabolism, 25(5), 1075-1090.
